UPB
Upstream Bio, Inc.
$7.27
+0.13 (+1.82%)
At close · Jul 15
Market Cap
$395.91M
Shares
54,419,986
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.27
Open$7.12
Day$7.08–7.32
52W$5.85–33.68
Avg vol 30d621K
Short int4.1M · 7.5% float · 5.7d
Short vol55%
Last earningsMay 13, 2026
DataOct 2024–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−57%
below
Price vs 50-day avg
−5%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
−77%
trailing
YTD return
−73%
this year
Relative strength
−87%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $17 — 200d above 50d
Institutional flow
Distributing
5 of 142 funds reported for Jun 30 · net -297.5K sh shares · +1 new
Insider flow
Distributing
Net -$30.6K over 90 days · 100% sells
Short interest
Rising
7.54% of float · ▲ +5.3% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
142 holders — near 1-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+52%
Y/Y
Free cash flow
$-133.4M
Balance sheet
$101.6M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−57%
Bearish
Price vs 50-day avg
−5%
Bearish
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $8 › 200d $17 — 200d above 50d
Institutional flow
Distributing
5 of 142 funds reported for Jun 30 · net -297.5K sh shares · +1 new
Insider flow
Distributing
Net -$30.6K over 90 days · 100% sells
Short interest
Rising
7.54% of float · ▲ +5.3% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
142 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $7 · 5%
52-wk high $34
vs 200-day avg -57%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UPB
this stock
Upstream Bio, Inc.
|
$395.91M | -73.2% | -0.4% | — | 7.5% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.2% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.66B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$53.96B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UPB | -8.9% | +19.2% | -76.6% | +5.1% | -73.2% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -10.2% | +19.3% | -86.7% | +4.0% | -83.9% |